Curcumin–piperine complex

The Curcumin–piperine complex is a pharmacological combination of two bioactive natural compounds: curcumin, a polyphenol derived from turmeric (Curcuma longa), and piperine, an alkaloid found in black pepper (Piper nigrum) [1, 7]. This entity is not a single biological target (such as a receptor or enzyme) but rather a therapeutic formulation designed to overcome the poor oral bioavailability of curcumin [2, 8]. Piperine acts as a potent bio-enhancer by inhibiting metabolic enzymes such as UDP-glucuronosyltransferase (UGT) and cytochrome P450 3A4 (CYP3A4), as well as efflux transporters like P-glycoprotein, thereby reducing the rapid glucuronidation and excretion of curcumin [2, 12]. Once stabilized in the systemic circulation, curcumin exerts pleiotropic effects by modulating multiple molecular targets, including the inhibition of pro-inflammatory transcription factors like NF-κB and enzymes such as COX-2 and LOX [4, 14]. The complex is widely studied for its synergistic potential in treating chronic inflammatory conditions, metabolic syndrome, and various cancers [7, 10]. Furthermore, the combination has been shown to enhance the antioxidant capacity of the body and improve glycemic indices in diabetic patients [7, 11]. Despite its natural origin, the complex requires careful clinical monitoring due to its potential to alter the pharmacokinetics of co-administered pharmaceutical drugs [9, 12].

Other names

Curcumin-piperine combinationCurcumin-piperine formulationTurmeric and black pepper extractBioPerine-curcumin

Piperine enhances curcumin bioavailability by inhibiting hepatic and intestinal glucuronidation (via UGT inhibition) and cytochrome P450 3A4 (CYP3A4) activity [2, 12]. Curcumin subsequently modulates multiple signaling pathways, including the inhibition of NF-κB, COX-2, and TNF-α [4, 14].